Skip to main content
生物谷 logo

生物谷 — Investor Relations & Filings

Ticker · 920266 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2023-06-14 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920266

About 生物谷

https://www.bioon.com/

Bio-Valley specializes in the research, development, and manufacturing of botanical-based therapeutic solutions, with a primary focus on cardiovascular and cerebrovascular health. The company is a leader in the industrialization of Erigeron breviscapus (Dengzhanhua), a botanical resource used for treating ischemic stroke and its sequelae. Its core product portfolio includes Dengzhan Shengmai Capsules and Dengzhan Xixin Injection, which are utilized in clinical settings for their neuroprotective and microcirculation-improving properties. Bio-Valley maintains a comprehensive value chain encompassing botanical cultivation, standardized extraction, and large-scale production. By leveraging advanced extraction technologies and rigorous quality control, the company provides evidence-based solutions for chronic disease management and geriatric care.

Recent filings

Filing Released Lang Actions
关于对北京证券交易所2022年年报问询函的回复
Regulatory Filings
2023-06-14 Chinese
第四届董事会第十七次会议决议公告
Board/Management Information Classification · 100% confidence The document is an announcement of resolutions from the 17th meeting of the 4th Board of Directors of Yunnan Biovalley Pharmaceutical Co., Ltd. It details meeting attendance, voting results on board committee member adjustments, and related procedural information. There is no financial data, no mention of annual or quarterly reports, no audit information, and no investor presentation content. The focus is on board decisions and changes in board committee membership. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management. The document length is short and it is not a report but an announcement of board meeting resolutions.
2023-06-12 Chinese
关于调整公司第四届董事会相关专门委员会的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding adjustments to the company's fourth board of directors' specialized committees, including changes to the nomination committee and the remuneration and assessment committee. It references compliance with governance standards and the company's articles of association. There is no financial data, earnings information, or report publication mentioned. The content focuses on board/management changes and governance structure adjustments. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS.
2023-06-12 Chinese
关于北京证券交易所问询函的回复
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the board of directors of Yunnan Shengwu Gu Pharmaceutical Co., Ltd. responding to an inquiry from the Beijing Stock Exchange Listing Company Management Department. It addresses shareholder proposals, board composition, company governance, and the impact of these matters on daily operations. The content focuses on governance issues, compliance with company law and articles of association, and the status of board and shareholder meetings. There are no financial statements, earnings data, or audit information presented. The document is a regulatory announcement related to corporate governance and shareholder relations, not a full report or financial filing. It is also relatively short (3550 characters) and structured as a formal reply to regulatory inquiries. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-06-12 Chinese
独立董事关于第四届董事会第十七次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is a formal announcement from independent directors regarding opinions on adjustments to certain members of the company's board committees. It references the company's board meeting and legal compliance but does not contain financial data, earnings, or detailed report content. The document is short (668 characters) and focuses on board/management committee changes. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2023-06-12 Chinese
关于北京证券交易所问询函的回复
Regulatory Filings Classification · 95% confidence The document is a detailed response from a company to an inquiry letter issued by the Beijing Stock Exchange regarding the company's 2022 annual report. It discusses the appointment of a third-party professional institution to assist in verification related to the inquiry, the establishment of a departure audit system, the current status and operation of the board of directors, and other matters related to shareholder proposals and board decisions. The document references the 2022 annual report inquiry but does not contain the annual report itself or financial statements. It is a regulatory response to an inquiry letter, providing explanations and updates on governance and compliance matters. The document is not a full annual report (10-K), audit report (AR), or interim report (IR), nor is it a simple announcement or certification. It fits best under Regulatory Filings (RNS) as it is a formal regulatory response to an inquiry from the stock exchange.
2023-06-06 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.